{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T21:02:39Z","timestamp":1789419759017,"version":"build-2803163510"},"reference-count":16,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2001,1,1]],"date-time":"2001-01-01T00:00:00Z","timestamp":978307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,24]],"date-time":"2019-12-24T00:00:00Z","timestamp":1577145600000},"content-version":"vor","delay-in-days":6931,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2001,1]]},"DOI":"10.1023\/a:1008369615016","type":"journal-article","created":{"date-parts":[[2002,12,22]],"date-time":"2002-12-22T14:41:38Z","timestamp":1040568098000},"page":"119-122","source":"Crossref","is-referenced-by-count":17,"title":["The effect of increasing topotecan infusion from 30 minutes to 4 hours on the duration of exposure in cerebrospinal fluid"],"prefix":"10.1016","volume":"12","author":[{"given":"W.C.","family":"Zamboni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.I.","family":"L\u00fcftner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.J.","family":"Egorin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Schweigert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Sezer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Richter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.J.","family":"Natale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Possinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1023\/A:1008369615016_bb0010","series-title":"Principles and Practices of Pediatnc Oncology","first-page":"633","article-title":"Tumors of the central nervous system","author":"Packer RJ","year":"1994"},{"key":"10.1023\/A:1008369615016_bb0015","first-page":"107","volume":"5","author":"Blaney","year":"1991","journal-title":"Pharmacologic approaches to the treatment of meningeal malignancy Oncology"},{"key":"10.1023\/A:1008369615016_bb0020","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/BF00173684","article-title":"Pharmacologic strategies for the treatment of meningeal malignancy","volume":"14","author":"Blaney","year":"1996","journal-title":"Invest New Drugs"},{"key":"10.1023\/A:1008369615016_bb0025","first-page":"2537","article-title":"A four-hour topotecan infusion achieves cytotoxic exposure throughout the neuraxis in the nonhuman primate model Implications for treatment of children with metastatic medulloblastoma","volume":"4","author":"Zamboni","year":"1998","journal-title":"Clin Cancer Res"},{"key":"10.1023\/A:1008369615016_bb0030","first-page":"1731","article-title":"Intermittent exposure of medulloblastoma cells to topotecan produces growth inhibition equivalent to continuous exposure","volume":"3","author":"Danks","year":"1997","journal-title":"Clin Cancer Res"},{"key":"10.1023\/A:1008369615016_bb0035","first-page":"725","article-title":"Plasma and cerebrospinal fluid pharma-cokinetic study of topotecan in nonhuman primates","volume":"53","author":"Blaney","year":"1993","journal-title":"Cancer Res"},{"key":"10.1023\/A:1008369615016_bb0040","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/BF00688317","article-title":"Cerebrospinal pharma-cokinetics and penetration of continuous infusion topotecan in children with central nervous system tumors","volume":"37","author":"Baker","year":"1996","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1023\/A:1008369615016_bb0045","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/BF00686188","article-title":"Efficacy of topoisomerase I inhibitors, topotecan and mnotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors","volume":"36","author":"Houghton","year":"1995","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1023\/A:1008369615016_bb0050","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1200\/JCO.1994.12.9.1946","article-title":"Clinical pharma-codynamics of continuous infusion topotecan in children Systemic exposure predicts hematologic toxicity","volume":"12","author":"Stewart","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.1023\/A:1008369615016_bb0055","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/0731-7085(90)80122-6","article-title":"High-performance liquid chromatographic analysis of the new antitumor drug SK & F 104864-A (NSC 609699) in plasma","volume":"8","author":"Beijnen","year":"1990","journal-title":"J Pharm Biomed Anal"},{"key":"10.1023\/A:1008369615016_bb0060","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1097\/00043426-199611000-00004","article-title":"Phase I trial and pharmacokinetic (PK) and pharmacodynamic (PD) study of topotecan using a five-day course in children with refractory solid tumors A pediatnc oncology group study","volume":"18","author":"Tubergen","year":"1996","journal-title":"J Pediatr Hematol Oncol"},{"key":"10.1023\/A:1008369615016_bb0065","series-title":"ADAPT II User\u2019s Guide Biomedical Simulations Resources Los Angeles University of Southern California","author":"D\u2019Argemo","year":"1990"},{"key":"10.1023\/A:1008369615016_bb0070","first-page":"131","article-title":"Poplack DG Prophylaxis and treatment of leukemia in the central nervous system and other sanctuaries","volume":"12","author":"Bleyer","year":"1985","journal-title":"Semin Oncol"},{"key":"10.1023\/A:1008369615016_bb0075","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1200\/JCO.1983.1.5.317","article-title":"Reduction in central nervous system leukemia with a pharmacokinetically derived intrathecal methotrexate dosage regimen","volume":"1","author":"Bleyer","year":"1983","journal-title":"J Clin Oncol"},{"key":"10.1023\/A:1008369615016_bb0080","series-title":"Pharmacokinelics","author":"Gibaldi","year":"1982"},{"key":"10.1023\/A:1008369615016_bb0085","first-page":"323","article-title":"Individualized topotecan (TPT) dosing attains cytotoxic CSF TPT exposure in children with high-risk medulloblastoma","author":"Ma","year":"1999","journal-title":"Proc Soc Neuro Oncol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419472347?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419472347?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/12\/1\/119\/19478429\/12-1-119.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,20]],"date-time":"2020-02-20T06:55:29Z","timestamp":1582181729000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419472347"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,1]]},"references-count":16,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2001,1]]}},"alternative-id":["S0923753419472347"],"URL":"https:\/\/doi.org\/10.1023\/a:1008369615016","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2001,1]]}}}